EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 151 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,466 | -79.8% | 410 | -75.2% | 0.00% | – |
| Q2 2023 | $32,076 | +267200.0% | 1,650 | +302.4% | 0.00% | – |
| Q1 2023 | $12 | 0.0% | 410 | 0.0% | 0.00% | – |
| Q4 2022 | $12 | -99.9% | 410 | 0.0% | 0.00% | – |
| Q3 2022 | $13,000 | -51.9% | 410 | -33.5% | 0.00% | – |
| Q2 2022 | $27,000 | 0.0% | 617 | +12.8% | 0.00% | – |
| Q1 2022 | $27,000 | -81.0% | 547 | -82.3% | 0.00% | -100.0% |
| Q4 2021 | $142,000 | -16.0% | 3,085 | +1.6% | 0.00% | 0.0% |
| Q3 2021 | $169,000 | -11.5% | 3,035 | -32.1% | 0.00% | 0.0% |
| Q2 2021 | $191,000 | -16.2% | 4,472 | -18.3% | 0.00% | 0.0% |
| Q1 2021 | $228,000 | -10.6% | 5,472 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $255,000 | +152.5% | 5,472 | +130.5% | 0.00% | +100.0% |
| Q3 2020 | $101,000 | – | 2,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |